Department of Urology 'L. Giuliani', University of Genoa, Genoa, Italy.
BJU Int. 2012 Dec;110(11 Pt B):E744-9. doi: 10.1111/j.1464-410X.2012.11554.x. Epub 2012 Nov 7.
What's known on the subject? and What does the study add? Upper Urinary Tract (UUT) Transitional Cell Carcinoma (TCC) is an uncommon disease and represents approximately 5% of all urothelial carcinomas. We report our series on 73 patients treated with Kidney Sparing Surgery for UUT TCC. Good results have been achieved in terms of oncological outcome comparing this conservative approach to the radical nephrourectomy.
• To report the long-term oncological outcome in patients with transitional cell carcinoma of the ureter electively treated with kidney-sparing surgery. • To compare our data with the few series reported in the literature.
• We considered 73 patients with transitional cell carcinoma of the distal ureter treated in five Italian Departments of Urology. • The following surgeries were carried out: 38 reimplantations on psoas hitch bladder (52%), 21 end-to-end anastomoses (28.8%), 11 direct ureterocystoneostomies (15.1%) and three reimplantations on Boari flap bladder (4.1%). • The median follow-up was 87 months.
• Tumours were pTa in 42.5% of patients, pT1 in 31.5%, pT2 in 17.8% and pT3 in 8.2%. • Recurrence of bladder urothelial carcinoma was found in 10 patients (13.7%) after a median time of 28 months. • The bladder recurrence-free survival at 5 years was 82.2%. • The overall survival at 5 years was 85.3% and the cancer-specific survival rate at 5 years was 94.1%.
• Our data show that segmental ureterectomy procedures do not result in worse cancer control compared with data in the literature regarding nephroureterectomy.
报告在选择性接受保留肾单位手术治疗的输尿管移行细胞癌患者的长期肿瘤学结果。
将我们的数据与文献中报道的少数系列进行比较。
我们考虑了 5 个意大利泌尿外科部门治疗的 73 例远端输尿管移行细胞癌患者。
进行了以下手术:38 例在腰大肌皮瓣膀胱上进行再植入(52%),21 例进行端端吻合术(28.8%),11 例直接进行输尿管-肾盂吻合术(15.1%)和 3 例在 Boari 皮瓣膀胱上进行再植入(4.1%)。
中位随访时间为 87 个月。
肿瘤在 42.5%的患者中为 pTa,在 31.5%的患者中为 pT1,在 17.8%的患者中为 pT2,在 8.2%的患者中为 pT3。
在中位时间为 28 个月时,10 例患者(13.7%)发现膀胱尿路上皮癌复发。
5 年膀胱无复发生存率为 82.2%。
5 年总生存率为 85.3%,5 年癌症特异性生存率为 94.1%。